Envestnet Portfolio Solutions Inc. Has $688,000 Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,094 shares of the medical research company’s stock after purchasing an additional 388 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Bio-Rad Laboratories were worth $688,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BIO. one8zero8 LLC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at about $221,000. Natixis Advisors LLC increased its holdings in Bio-Rad Laboratories by 10.6% in the 4th quarter. Natixis Advisors LLC now owns 45,713 shares of the medical research company’s stock valued at $15,017,000 after buying an additional 4,390 shares during the period. Picton Mahoney Asset Management raised its position in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after buying an additional 35 shares in the last quarter. Atala Financial Inc acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $87,000. Finally, LBP AM SA bought a new position in Bio-Rad Laboratories in the fourth quarter valued at approximately $1,444,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BIO has been the topic of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Trading Up 0.3 %

NYSE BIO opened at $257.38 on Tuesday. Bio-Rad Laboratories, Inc. has a twelve month low of $244.00 and a twelve month high of $387.99. The business’s fifty day moving average is $301.32 and its 200 day moving average is $324.70. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.21 billion, a price-to-earnings ratio of -3.96 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.